US-based SRI International has been contracted by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases and the Division of AIDS (NIAID-DAIDS) to provide development and manufacturing support for HIV microbicides and other non-vaccine pre-exposure (PreP) agents.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Valued at up to $150m, the contract requires SRI to provide a wide range of preclinical product development services for candidate HIV-prevention products developed as part of investigator-initiated studies or from collaborations with outside companies and organisations.

Under the seven-year contract, the company’s division SRI Biosciences will manufacture and characterise drug products to support the progression of microbicide and PreP agents through both preclinical and clinical studies.

"The use of non-vaccine biomedical prevention products could reduce the estimated 5,000 new HIV infections per day worldwide."

The contract also covers support for specific activities required by the US Food and Drug Administration to move products into clinical testing.

SRI Biosciences Center for Pharmaceutical and Chemical Technologies Formulations R&D director Gita Shankar said:  “Since the early 2000s, researchers at SRI International have been involved in drug development activities to help move many microbicides, PrEP agents, and multipurpose prevention technologies through IND-enabling studies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are very pleased to be given an opportunity to contribute to the acceleration of promising HIV products into clinical testing and the creation of a sustainable pipeline of prevention products and strategies.”

The use of non-vaccine biomedical prevention products could reduce the estimated 5,000 new HIV infections per day worldwide.

Image: SRI International will provide preclinical product development services for candidate HIV-prevention products. Photo: courtesy of SRI International.